Text and Data Mining valid from 2019-01-17
First Online: 17 January 2019
: C.A. has received funding support from Novartis, Merrimack, PUMA, Lilly, Merck, Cascadian/Seattle Genetics, Nektar, Tesaro and G1-Therapuetics; she has held uncompensated advisory roles with Novartis, Merrimack, Lilly, Genentech, Nektar and Cascadian/Seattle Genetics; she has held compensated advisory roles with PUMA, Merck and Eisai; and she has received royalties from UpToDate, Jones and Bartlett. M.S.A. has stock options in MimiVax and Doctible and has received grants and/or personal fees from Monteris Medical, AbbVie, BMS, AstraZeneca, Datar Genetics, CBT Pharmaceuticals, Kadmon Pharmaceuticals, Elsevier, NovoCure, Novartis, Incyte, Pharmacyclics, Tracon Pharmaceuticals, Prime Oncology, Flatiron, Merck, Bayer, Varian Medical Systems, VBI Vaccines and Caris Lifesciences. S.P. receives honoraria or consultation fees from AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, Pharma Mar, Pfizer, Regeneron, Sanofi, Seattle Genetics and Takeda; she has given talks in an organized public event for AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Merck Sharp and Dohme, Novartis, Pfizer and Takeda; and she is a (sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Merck Serono, Novartis, MedImmune and Pfizer. P.S.S. receives research funding from MedImmune. The remaining authors declare no competing interests.